Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Articles

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.

Health Equity & Access Weekly Roundup: January 18, 2024

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their pharmacies through network exclusions and targeted marketing. 

Insurer-PBM Firms Dominate Medicare Part D Market, Steering Patients to Their Pharmacies

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.


Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

In-depth interviews with decision-makers, stakeholders, and researchers on timely and emerging trends in clinical data, health policy, value-based care, and more!

1rem

Emerging Therapies for Interstitial Lung Disease

Videos

An Overview of Interstitial Lung Disease

Interstitial Lung Disease: Risk Factors and Comorbidities

Establishing a Diagnosis of Interstitial Lung Disease

Approaching Interstitial Lung Disease Management

Interstitial Lung Disease: Guidelines for Therapy

Economic Burden of Interstitial Lung Disease

Treatment Options for Interstitial Lung Disease

Interstitial Lung Disease: Immunosuppressive and Nonpharmacological Options

Treating Progressive Fibrosing Interstitial Lung Disease

Systemic Sclerosis and Interstitial Lung Disease

Treatment Goals and Options for Systemic Sclerosis Interstitial Lung Disease

Unmet Needs and Future Directions in ILD